1Cademy - Figure 2. Changes in Brescia COVID-19 Respiratory Severity Scale (BCRSS) among 100 severe COVID-19 patients in Brescia, Italy during 10-day follow-up after Tocilizumab (TCZ) infusion

Learn Before

Outcomes among 100 severe COVID-19 patients in Brescia, Italy 24–72 h after Tocilizumab (TCZ) infusion
Outcomes among 100 severe COVID-19 patients in Brescia, Italy 10 days after Tocilizumab (TCZ) infusion

Concept

Figure 2. Changes in Brescia COVID-19 Respiratory Severity Scale (BCRSS) among 100 severe COVID-19 patients in Brescia, Italy during 10-day follow-up after Tocilizumab (TCZ) infusion

BCRSS scores decreased overall for all patients given TCZ transfusion, showing clinical improvements, but not necessarily statistical significance.

Updated 2020-06-19

Contributors are:

Lisa Mayer

🏆 3

Who are from:

University of Michigan - Ann Arbor

🏆 3

References

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy

Learn After

Brescia COVID-19 Respiratory Severity Scale (BCRSS)

Learn Before

Related

Learn After